InAADR

Protein Information

Protein Name: D(1A) dopamine receptor (P21728)
Gene Name: DRD1
Description: D(1A) dopamine receptor
PDB ID:
Protein Family:
Protein Category: Membrane Receptors

This panel provides drug-protein interaction and their ADRs along with references

Interacting Drugs Toxicity Mechanism Reference
Gabapentin Akathisia Dopamine receptor hypersensitivity hypothesis and the hypothesis of mitochondrial respiratory chain inhibition are evidences for the hypotheses of the pathogenetic mechanisms leading to akathisia(extrapyramidal side effects). [ ADR Type 1 ] Cell-mediated side effects of psychopharmacological treatment
Gabapentin Dystonic Reactions Dopamine receptor hypersensitivity hypothesis and the hypothesis of mitochondrial respiratory chain inhibition are evidences for the hypotheses of the pathogenetic mechanisms leading to dystonic reactions(extrapyramidal side effects) [ ADR Type 1 ] Cell-mediated side effects of psychopharmacological treatment
Gabapentin Parkinsonism Dopamine receptor hypersensitivity hypothesis and the hypothesis of mitochondrial respiratory chain inhibition are evidences for the hypotheses of the pathogenetic mechanisms leading to parkinsonism(extrapyramidal side effects) [ ADR Type 1 ] Cell-mediated side effects of psychopharmacological treatment
Gabapentin Tardive Dyskinesias Dopamine receptor hypersensitivity hypothesis and the hypothesis of mitochondrial respiratory chain inhibition are evidences for the hypotheses of the pathogenetic mechanisms leading to tardive dyskinesias(extrapyramidal side effects). [ ADR Type 1 ] Cell-mediated side effects of psychopharmacological treatment
Haloperidol Tardive Dyskinesia HP metabolites bind to the transporters for dopamine and serotonin@which is concerning a possible role of HP metabolites in the development of tardive dyskinesia. [ ADR Type 2 ] Effects of haloperidol metabolites on neurotransmitter uptake and release: possible role in neurotoxicity and tardive dyskinesia
opiates Hypomotility Melanotropin release inhibiting factor (MIF) and its analog cyclo(Leu-Gly) (CLG) facilitate dopamine (DA) receptor aGOnist binding and inhibit DA receptor supersensitivity induced by neuroleptics and opiates@which leads to hypomotility [ ADR Type 1 ] Effect of cyclo(Leu-Gly) on reserpine-induced hypomotility and increases in cortical beta-adrenergic receptors

This panel provides information on drug category

Toxicity Source

InAADR: Drug-Protein-ADRs database